Stock Rating Downgrade
The Value Trend Rating for Biogen Inc (NASDAQ: BIIB) weakened recently from C to D reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next report.
Recent Price Action
On 1/24/25, Biogen Inc (NASDAQ: BIIB) stock increased 1.8%, closing at $146.20. This advance was accompanied by normal trading volume. The stock has been extremely weak relative to the market over the last nine months but has risen 3.7% during the last week.
Current PriceTarget Research Rating
Biogen has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Biogen has a good Appreciation Score of 79 but a very low Power Rating of 8, leading to the Negative Value Trend Rating.
Be the first to comment